C5 and paroxysmal nocturnal hemoglobinuria: The molecule showed to be more potent in decreasing C5 levels and hemolysis in humans and animal models compared to eculizumab and ravulizumab [110], pushing its further investigation for the treatment of PNH and other complement-mediated diseases.